MedTrace Logo

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

NCT00765674 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1191

Last updated 2011-05-09

Study results available
· View outcomes & findings →

Summary

This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension.

Conditions

Interventions

DRUG

Aliskiren

150 and 300 mg tablets

DRUG

Amlodipine

5 and 10 mg capsules

DRUG

Hydrochlorothiazide (HCTZ)

12.5 and 25 mg capsules

DRUG

Placebo

tablet

DRUG

Placebo

capsules

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States
  • Australia
  • Canada
  • Denmark
  • Germany
  • Israel
  • Italy
  • Latvia
  • Lithuania
  • Romania
  • Sweden
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00765674 on ClinicalTrials.gov